All‐cause mortality ‐ formoterol and budesonide vs salmeterol and fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/budesonide vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol/budesonide vs salmeterol/budesonide · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (low certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in asthma‐related non‐fatal serious adverse events ‐… compared with salmeterol/ICS (low certainty).
5 findings from 1 review
OR 0.69 [0.37, 1.26]
7 studies · 5935 participants
Low
OR 1.01 [0.06, 16.24]
5 studies · 1510 participants
Very low
OR 7 [0.14, 353.37]
1 study · 722 participants
Very low
Show 2 more findings
Mortality (all‐cause) ‐ formoterol versus salbutamol ( · adults, chronic asthma: all‐cause mortality
1 finding from 1 review
All‐cause mortality ‐ formoterol/mometasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/mometasone vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).
1 finding from 1 review
All‐cause mortality ‐ formoterol/fluticasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/fluticasone vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).
1 finding from 1 review
All‐cause mortality formoterol/budesonide vs salmeterol/budesonide · adults, chronic asthma: all‐cause mortality
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol and budesonide vs salmeterol and fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal SAE ‐ Adults · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol/mometasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/mometasone… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone… compared with salmeterol/ICS (low certainty).
1 finding from 1 review
Exacerbations needing hospitalisation · people with asthma
Formoterol showed no clear difference in patients with an exacerbation requiring hospitalisation compared with short‐acting beta2‐agonist (moderate certainty).
1 finding from 1 review
Exacerbations requiring oral corticosteroids ‐ adults · people with asthma
Formoterol probably leads to lower patients with an exacerbation requiring a course of oral… compared with short‐acting beta2‐agonist (moderate certainty).
1 finding from 1 review
Fatal serious adverse events · people with asthma
Formoterol showed no clear difference in fatal serious adverse events (all‐cause) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
Patients with a serious adverse event (all cause) · people with asthma
Formoterol showed no clear difference in patients with a serious adverse event (all cause) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
Asthma‐related serious adverse event · people with asthma
Formoterol showed no clear difference in patients with a serious adverse event (asthma related) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
Withdrawals due to any reason · people with asthma
Formoterol may leads to higher withdrawals (any reason) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
All‐cause mortality in adults · people with asthma
1 finding from 1 review
All‐cause mortality in children · people with asthma
1 finding from 1 review
All‐cause SAEs in adults · people with asthma
Regular formoterol showed no clear difference in all‐cause SAEs in adults compared with regular salmeterol (low certainty).
1 finding from 1 review